Metformin Use Linked With Decreased Risk of Glaucoma

Metformin is the most commonly prescribed diabetes medication.   It acts differently from the other hypoglycemic meds.  Metformin decreases glucose production by the liver, decreases absorption of glucose in the GI tract, and improves insulin sensitivity.    This way it improves blood sugar control.

Metformin is primarily used to treat T2D but recently it’s being used to treat T1D and gestational diabetes.   It is also used to treat PCOS (polycystic ovary disease.

A new research suggests that it might also reduce the risk of developing glaucoma, a common diabetes complication.

June 17 image credit:  Diabetes Self Management

Image credit: Diabetes Self Management

Glaucoma is the leading cause of blindness, affecting more than 3 million Americans. The most common form, open-angle glaucoma, affects 2.7 million Americans over age 40 and occurs when the eye’s drainage canals become blocked, leading to an increase in eye pressure and damage to the optic nerve.

The researchers found that people prescribed the highest amount of metformin (more than 1,110 grams in two years) had a 25% decreased risk of developing open-angle glaucoma compared to those who were prescribed no metformin.    However due to the nature of the study, the findings can’t prove that metformin prevents glaucoma.    As of this writing, it is too early to recommend that diabetics be given higher doses of metformin based on the study.


Source: Diabetes Self Management


This entry was posted in diabetes, diabetes management and tagged , , , , , , . Bookmark the permalink.

2 Responses to Metformin Use Linked With Decreased Risk of Glaucoma

  1. Thanks for the comment. I am not on any diabetes meds so far, knock on the wood so had no idea what the side effects of Metformin can be.

    Liked by 1 person

  2. Tessa says:

    Both my mother and i suffered increased blood sugars on Metformin. I take Glipizide and it is free from my pharmacy. Metformin is too, but I won’t take it.

    Liked by 1 person

Comments are closed.